Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Striverdi Respimat 2.5 microgram, solution for inhalation

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Olodaterol hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Olodaterol hydrochloride
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

How to take it

Striverdi Respimat 4. Possible side effects 5. How to store Striverdi Respimat

Possible side effects

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Driving and using machines No studies on the effects on the ability to drive and use machines have been performed. If you feel dizzy while taking this medicine, do not drive or use any tools or machines. Striverdi Respimat contains Benzalkonium chloride This medicine contains 0.0011 mg benzalkonium chloride in each actuation. Benzalkonium chloride may cause wheezing and breathing difficulties (bronchospasm), especially if you have asthma.

3. How to take Striverdi Respimat

Stop taking this medicine and tell your doctor straight away if you notice any of the following serious side effects – you may need urgent medical treatment:

  • Immediate allergic reactions such as rash, nettle rash (urticaria), swelling of the mouth and face or sudden difficulties in breathing (angioneurotic oedema)
  • Unexpected tightness of the chest, coughing or wheezing or breathlessness immediately after inhalation (bronchospasm) The side effects described below have been experienced by people taking this medicine and they are listed according to frequency as either uncommon or rare. Uncommon (may affect up to 1 in 100 people):

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

  • Nasopharyngitis (runny nose)
  • Dizziness
  • Rash

Striverdi Respimat is for inhalation use only.

Rare (may affect up to 1 in 1,000 people):

Dosage

  • Arthralgia (joint pain)
  • Hypertension

The recommended dose is: Striverdi Respimat is effective for 24 hours so you will need to take this medicine only ONCE A DAY, if possible at the same time of the day. Each time you use it take TWO PUFFS. As COPD is a long-term disease take this medicine every day and not only when you experience breathing problems. Do not take more than the recommended dose. Make sure that you know how to use your Respimat re-usable inhaler properly. The instructions on how to use the Respimat re-usable inhaler are provided at the end of this leaflet, see 'Instructions on how to use the Respimat re-usable inhaler'. Use in children and adolescents There is no relevant use of this medicine in the paediatric population (under 18 years). If you take more Striverdi Respimat than you should You may be at a higher risk of experiencing a side effect such as chest pain, high or low blood pressure, faster or irregular heartbeat or feeling of heart beat, dizziness, nervousness, difficulty in sleeping, anxiety, headache, shaking, dry mouth, muscle cramps, nausea, fatigue, malaise, low blood levels of potassium (which may cause symptoms of muscle spasm, muscle weakness or abnormal heart rhythm), high blood sugar, or too much acid in your blood (which may cause symptoms of nausea, vomiting, weakness, muscle cramps and more rapid breathing). If you forget to take Striverdi Respimat If you forget to inhale a dose, inhale just one dose at the usual time the next day. Do not take a double dose to make up for a forgotten dose. If you stop taking Striverdi Respimat Before you stop taking Striverdi Respimat, you should talk to your doctor or your pharmacist. If you stop taking Striverdi Respimat the signs and symptoms of COPD may worsen. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

You may also experience side effects which are known to occur with certain medicines for breathing problems similar to this medicine (beta-adrenergic agents). These may be faster or irregular heartbeat or feeling of heart beat, chest pain, high or low blood pressure, shaking, headache, nervousness, difficulty in sleeping, dizziness, dry mouth, nausea, muscle cramps, fatigue, malaise, low blood levels of potassium (which may cause symptoms of muscle spasm, muscle weakness or abnormal heart rhythm), high blood sugar, or too much acid in your blood (which may cause symptoms of nausea, vomiting, weakness, muscle cramps and more rapid breathing). Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Striverdi Respimat Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and on the cartridge label after EXP. The expiry date refers to the last day of the month. Do not freeze. In-use shelf life Exchange the cartridge latest three months after insertion. Do not use the Respimat re-usable inhaler for more than one year. Recommended use: 6 cartridges per inhaler Note: The functioning of the Respimat re-usable inhaler has been demonstrated in tests for 540 actuations (corresponding to 9 cartridges). Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information What Striverdi Respimat contains The active substance is olodaterol. The delivered dose is 2.5 microgram olodaterol (as hydrochloride) per puff. The delivered dose is the dose which is available for the patient after passing the mouthpiece. The other ingredients are: Benzalkonium chloride, disodium edetate, purified water, and citric acid (anhydrous) What Striverdi Respimat looks like and contents of the pack Striverdi Respimat 2.5 microgram is composed of one cartridge with inhalation solution and one Respimat inhaler. The cartridge has to be inserted into the inhaler before the first use. Single pack: 1 Respimat re-usable inhaler and 1 cartridge, providing 60 puffs (30 medicinal doses) Triple pack: 1 Respimat re-usable inhaler and 3 cartridges, providing 60 puffs (30 medicinal doses) each Single refill pack: 1 cartridge, providing 60 puffs (30 medicinal doses) Triple refill pack: 3 cartridges, providing 60 puffs (30 medicinal doses) each Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer The marketing authorisation holder for Striverdi Respimat is: Boehringer Ingelheim International GmbH Binger Straße 173 55216 Ingelheim am Rhein Germany The manufacturer for Striverdi Respimat is: Boehringer Ingelheim Pharma GmbH & Co. KG Binger Straße 173 55216 Ingelheim am Rhein Germany This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names: Austria, Liechtenstein, Belgium, Luxembourg, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Malta, United Kingdom (Northern Ireland), Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden: Striverdi Respimat Bulgaria: Стриверди Респимат This leaflet was last revised in 07/2024.

Instructions on how to use the Respimat re-usable inhaler

abcd

TWO PUFFS ONCE DAILY

Respimat is an inhaler device that generates a spray for inhalation. Respimat is for you only. One cartridge delivers multiple doses. The Respimat re-usable inhaler allows for the replacement of the cartridge, and can be used with up to 6 cartridges. Read these instructions before you start using Striverdi Respimat. You will need to use this inhaler only ONCE A DAY. Each time you use it take TWO PUFFS.

Respimat®

Cartridge

Cap

Mouthpiece Air vents Dose-release button

Prepare for use

1 2

Daily use Safety catch Clear base

Remove clear base

  • Keep the cap closed.
  • Press the safety catch while pulling off the clear base with your other hand.

Answers to Common Questions It is difficult to insert the cartridge deep enough.

TURN

Arrows

  • Keep the cap closed.
  • TURN the clear base in the direction of the arrows on the label until it clicks (half a turn).

Insert cartridge

  • Insert the cartridge into the inhaler.
  • Place the inhaler on a firm surface and push down firmly until it clicks into place.

Cap

"CLICK"

OPEN

Cartridge counter Dose Indicator

Clear base

Front

3

Put back clear base

Track cartridge and put the clear base back

  • Mark the check-box on inhaler's label to track the number of cartridges.
  • Put the clear base back into place until it clicks.

Back

  • If Striverdi Respimat has not been used for more than 7 days release one puff towards the ground.
  • If Striverdi Respimat has not been used for more than 21 days repeat steps 4 to 6 under 'Prepare for use' until a cloud is visible. Then repeat steps 4 to 6 three more times.

How to care for your Respimat re-usable inhaler Clean the mouthpiece including the metal part inside the mouthpiece with a damp cloth or tissue only, at least once a week. Any minor discoloration in the mouthpiece does not affect your Respimat re-usable inhaler performance. If necessary, wipe the outside of your Respimat re-usable inhaler with a damp cloth.

4

Arrows

Turn

  • Keep the cap closed.
  • Turn the clear base in the direction of the arrows on the label until it clicks (half a turn).

Cap

5

  • Breathe out slowly and fully.
  • Close your lips around the mouthpiece without covering the air vents. Point your Inhaler to the back of your throat.
  • While taking a slow, deep breath through your mouth, PRESS the dose-release button and continue to breathe in slowly for as long as comfortable.
  • Hold your breath for 10 seconds or for as long as comfortable.
  • Repeat Turn, Open, Press for a total of 2 puffs.
  • Close the cap until you use your inhaler again.

I cannot press the dose-release button.

Does the dose indicator on your cartridge display a white arrow on a red background? Your cartridge is used up. Insert a new cartridge.

Did you put the clear base back? If not, put the clear base back to unlock the inhaler. The Respimat re-usable inhaler only functions with the clear base in place.

It is difficult to remove the cartridge after it is used up. Pull and turn the cartridge at the same time.

I cannot turn or put the clear base back.

Air vent

TWO PUFFS ONCE DAILY

Open

Is the clear base loose and does the dose indicator on your cartridge display a white arrow on a red background? Your cartridge is used up. Insert a new cartridge. Did you turn the clear base already? If the clear base has already been turned, follow steps "OPEN" and "PRESS" under "Daily Use" to get your medicine.

My Striverdi Respimat has been used up too early.

  • Open the cap until it snaps fully open.

Did you use Striverdi Respimat as indicated (two puffs/once daily)? Each cartridge will last 30 days if used at two puffs once daily.

When to replace the inhaler

When to replace the Striverdi Respimat cartridge

When you have used an inhaler with 6 cartridges, get a new Striverdi Respimat pack containing an inhaler. Do not use the Respimat re-usable inhaler for more than one year, after having inserted the first cartridge.

The dose indicator shows how many puffs remain in the cartridge.

Press

6

Did you repeat TURN, OPEN, PRESS less than three times after inserting the cartridge? Repeat TURN, OPEN, PRESS three times after inserting the cartridge as shown in the steps 4 to 6 under "Prepare for use".

Does the dose indicator on your cartridge display a white arrow on a red background? Your cartridge is used up. Insert a new cartridge and put the clear base back.

PRESS

  • Point the inhaler toward the ground.
  • Press the dose-release button.
  • Close the cap.
  • Repeat steps 4-6 until a cloud is visible.
  • After a cloud is visible, repeat steps 4-6 three more times. Your inhaler is now ready to use and will deliver 60 puffs (30 doses).

Doserelease button

60 puffs remaining.

Less than 10 puffs remaining. Obtain a new cartridge.

x3 Steps 4-6

Your cartridge is used up. Turn the clear base to loosen it. Your inhaler is now in a locked position. Pull off the cartridge from the inhaler. Insert a new cartridge until it clicks (refer to step 2). The new cartridge will stick out more than the very first cartridge (continue with step 3). Remember to put the clear base back to unlock the inhaler.

Did you insert a cartridge? If not, insert a cartridge. Once your Striverdi RESPIMAT is assembled, do not remove the clear base or the cartridge until the cartridge is used up.

Are you replacing the cartridge? The new cartridge will stick out more than the very first cartridge. Insert it until it clicks, then replace the clear base.

Did you turn the clear base? If not, turn the clear base in a continuous movement until it clicks (half a turn).

  • OPEN the cap until it snaps fully open.

Safety catch

Did you accidentally turn the clear base before inserting the cartridge? Open the cap, press the dose-release button, then insert the cartridge.

My Striverdi Respimat doesn't spray.

Did you spray in the air often to check whether Striverdi Respimat is working? Once you have prepared Striverdi Respimat for use, no testspraying is required if used daily. Did you take off and put the clear base multiple times back? Do not remove the clear base before the cartridge is used up. Each time you take off the clear base without cartridge exchange, the dose counter records one puff and the remaining doses are reduced.

My Striverdi Respimat sprays automatically. Was the cap open when you turned the clear base? Close the cap, then turn the clear base. Did you press the dose-release button when turning the clear base? Close the cap, so the dose-release button is covered, then turn the clear base. Did you stop when turning the clear base before it clicked? Turn the clear base in a continuous movement until it clicks (half a turn). The dose counter will count each incomplete turn and the number of remaining doses is reduced. Was the cap open when you replaced the cartridge? Close the cap, then replace the cartridge.

Instructions on how to use the Respimat re-usable inhaler

abcd

TWO PUFFS ONCE DAILY

Respimat is an inhaler device that generates a spray for inhalation. Respimat is for you only. One cartridge delivers multiple doses. The Respimat re-usable inhaler allows for the replacement of the cartridge, and can be used with up to 6 cartridges. Read these instructions before you start using Striverdi Respimat. You will need to use this inhaler only ONCE A DAY. Each time you use it take TWO PUFFS.

Respimat®

Cartridge

Cap

Mouthpiece Air vents Dose-release button

Prepare for use

1 2

Daily use Safety catch Clear base

Remove clear base

  • Keep the cap closed.
  • Press the safety catch while pulling off the clear base with your other hand.

Answers to Common Questions It is difficult to insert the cartridge deep enough.

TURN

Arrows

  • Keep the cap closed.
  • TURN the clear base in the direction of the arrows on the label until it clicks (half a turn).

Insert cartridge

  • Insert the cartridge into the inhaler.
  • Place the inhaler on a firm surface and push down firmly until it clicks into place.

Cap

"CLICK"

OPEN

Cartridge counter Dose Indicator

Clear base

Front

3

Put back clear base

Track cartridge and put the clear base back

  • Mark the check-box on inhaler's label to track the number of cartridges.
  • Put the clear base back into place until it clicks.

Back

  • If Striverdi Respimat has not been used for more than 7 days release one puff towards the ground.
  • If Striverdi Respimat has not been used for more than 21 days repeat steps 4 to 6 under 'Prepare for use' until a cloud is visible. Then repeat steps 4 to 6 three more times.

How to care for your Respimat re-usable inhaler Clean the mouthpiece including the metal part inside the mouthpiece with a damp cloth or tissue only, at least once a week. Any minor discoloration in the mouthpiece does not affect your Respimat re-usable inhaler performance. If necessary, wipe the outside of your Respimat re-usable inhaler with a damp cloth.

4

Arrows

Turn

  • Keep the cap closed.
  • Turn the clear base in the direction of the arrows on the label until it clicks (half a turn).

Cap

5

  • Breathe out slowly and fully.
  • Close your lips around the mouthpiece without covering the air vents. Point your Inhaler to the back of your throat.
  • While taking a slow, deep breath through your mouth, PRESS the dose-release button and continue to breathe in slowly for as long as comfortable.
  • Hold your breath for 10 seconds or for as long as comfortable.
  • Repeat Turn, Open, Press for a total of 2 puffs.
  • Close the cap until you use your inhaler again.

I cannot press the dose-release button.

Does the dose indicator on your cartridge display a white arrow on a red background? Your cartridge is used up. Insert a new cartridge.

Did you put the clear base back? If not, put the clear base back to unlock the inhaler. The Respimat re-usable inhaler only functions with the clear base in place.

It is difficult to remove the cartridge after it is used up. Pull and turn the cartridge at the same time.

I cannot turn or put the clear base back.

Air vent

TWO PUFFS ONCE DAILY

Open

Is the clear base loose and does the dose indicator on your cartridge display a white arrow on a red background? Your cartridge is used up. Insert a new cartridge. Did you turn the clear base already? If the clear base has already been turned, follow steps "OPEN" and "PRESS" under "Daily Use" to get your medicine.

My Striverdi Respimat has been used up too early.

  • Open the cap until it snaps fully open.

Did you use Striverdi Respimat as indicated (two puffs/once daily)? Each cartridge will last 30 days if used at two puffs once daily.

When to replace the inhaler

When to replace the Striverdi Respimat cartridge

When you have used an inhaler with 6 cartridges, get a new Striverdi Respimat pack containing an inhaler. Do not use the Respimat re-usable inhaler for more than one year, after having inserted the first cartridge.

The dose indicator shows how many puffs remain in the cartridge.

Press

6

Did you repeat TURN, OPEN, PRESS less than three times after inserting the cartridge? Repeat TURN, OPEN, PRESS three times after inserting the cartridge as shown in the steps 4 to 6 under "Prepare for use".

Does the dose indicator on your cartridge display a white arrow on a red background? Your cartridge is used up. Insert a new cartridge and put the clear base back.

PRESS

  • Point the inhaler toward the ground.
  • Press the dose-release button.
  • Close the cap.
  • Repeat steps 4-6 until a cloud is visible.
  • After a cloud is visible, repeat steps 4-6 three more times. Your inhaler is now ready to use and will deliver 60 puffs (30 doses).

Doserelease button

60 puffs remaining.

Less than 10 puffs remaining. Obtain a new cartridge.

x3 Steps 4-6

Your cartridge is used up. Turn the clear base to loosen it. Your inhaler is now in a locked position. Pull off the cartridge from the inhaler. Insert a new cartridge until it clicks (refer to step 2). The new cartridge will stick out more than the very first cartridge (continue with step 3). Remember to put the clear base back to unlock the inhaler.

Did you insert a cartridge? If not, insert a cartridge. Once your Striverdi RESPIMAT is assembled, do not remove the clear base or the cartridge until the cartridge is used up.

Are you replacing the cartridge? The new cartridge will stick out more than the very first cartridge. Insert it until it clicks, then replace the clear base.

Did you turn the clear base? If not, turn the clear base in a continuous movement until it clicks (half a turn).

  • OPEN the cap until it snaps fully open.

Safety catch

Did you accidentally turn the clear base before inserting the cartridge? Open the cap, press the dose-release button, then insert the cartridge.

My Striverdi Respimat doesn't spray.

Did you spray in the air often to check whether Striverdi Respimat is working? Once you have prepared Striverdi Respimat for use, no testspraying is required if used daily. Did you take off and put the clear base multiple times back? Do not remove the clear base before the cartridge is used up. Each time you take off the clear base without cartridge exchange, the dose counter records one puff and the remaining doses are reduced.

My Striverdi Respimat sprays automatically. Was the cap open when you turned the clear base? Close the cap, then turn the clear base. Did you press the dose-release button when turning the clear base? Close the cap, so the dose-release button is covered, then turn the clear base. Did you stop when turning the clear base before it clicked? Turn the clear base in a continuous movement until it clicks (half a turn). The dose counter will count each incomplete turn and the number of remaining doses is reduced. Was the cap open when you replaced the cartridge? Close the cap, then replace the cartridge.

Contents of the pack and other information

1. What Striverdi Respimat is and what it is used for

abcd

Striverdi Respimat helps people who have chronic obstructive pulmonary disease (COPD) to breathe more easily. COPD is a long-term lung disease that causes shortness of breath and coughing. The term COPD is associated with the conditions chronic bronchitis and emphysema. As COPD is a long-term disease you should take this medicine every day and not only when you have breathing problems or other symptoms of COPD.

olodaterol

2.5 microgram, inhalation solution

Striverdi® Respimat® 314199-05

Striverdi® Respimat® 2.5 microgram, inhalation solution olodaterol

abcd

Striverdi Respimat contains the active substance olodaterol which is a long-acting bronchodilator (long acting beta 2 agonist) that helps to open your airways and makes it easier to get air in and out of the lungs. Regular use of this medicine can also help you when you have on-going shortness of breath related to your disease, and will help to minimise the effects of the disease on your everyday life.

2. What you need to know before you take Striverdi Respimat Do not take Striverdi Respimat

  • if you are allergic to olodaterol or any of the other ingredients of this medicine (listed in section 6) Warnings and precautions Talk to your doctor or pharmacist before taking Striverdi Respimat if you:
  • have asthma (you should not take this medicine for the treatment of asthma)
  • have diseases of the heart
  • have high blood pressure
  • have epilepsy
  • have a specific thyroid gland problem called thyrotoxicosis
  • have an abnormal widening of an artery called aneurysm
  • have diabetes

Perigord No: 824675 P2

Mandatory in

File information

TD

Printfile

Issue date of TD:

28.08.2015

Yes

Yes

PPM SKU:

P043722

No

Yes

PPM SKU version:

005

No

Yes

Issue date of artwork:

26.07.2024

No

Yes

Print colors:

BLACK

No

Yes

No

Yes

CYAN

MAGENTA

YELLOW Mat. No. Pack. Site:

314199-05

Min. font size:

10 pt

Legend case version:

V4.0 01/OCT/2012 (please do not change or remove it)

Technical information a = Batch No.

b = Expiry date

c = Manufacturing date

d = Price/Sample/Clinic

Technical colors BI-Diecut-Legendcase

Free area

Gluepoints

Additional Requirements of Packaging site Template name: TD-PI_710x308_90x35 Index: Only for BI-internal use, Template according to Drawing no.: SP-14-0090-001-B_Index_

MASS D: MASS E: MASS G:

0,35 mm 1,0 mm 0,65 mm

Example Technical information Control Code Type: Laetus mini

  • have severe liver problems as this medicine has not been studied in this patient population
  • have severe kidney problems as there is limited experience with this medicine in this patient population
  • are due to have a planned surgery During treatment with Striverdi Respimat
  • Stop taking the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. These may be signs of a condition called bronchospasm (see section 4).
  • If your breathing has got worse or if you experience rash, swelling or itching directly after using your inhaler, stop taking it and tell your doctor immediately (see section 4).
  • If you experience any side effects affecting your heart (increase in pulse rate, increase in blood pressure and/or increase in symptoms like chest pain), tell your doctor immediately (see section 4).
  • If you experience muscle spasm, muscle weakness or abnormal heart rhythm, consult your doctor as these may be related to low blood levels of potassium (see section 4). Striverdi Respimat is indicated for the maintenance treatment of your chronic obstructive pulmonary disease. It should not be used to treat a sudden attack of breathlessness or wheezing. Do not take Striverdi Respimat together with certain medicines containing long-acting ß-adrenergic agonists, like salmeterol or formoterol. If you regularly take certain medicines called shortacting ß-adrenergic agents, like salbutamol, continue to take these only to relieve acute symptoms like breathlessness. Children and adolescents This medicine should not be given to children or adolescents (below the age of 18 years). Other medicines and Striverdi Respimat Please tell your doctor or pharmacist if you are taking, or have recently taken any other medicines. In particular, please tell your doctor if you are taking:
  • certain medicines for breathing problems that are similar to this medicine (ß-adrenergic agents). You may be more likely to get side effects.
  • medicines called beta blockers that are used for high blood pressure or other heart problems (such as propranolol), or for the eye problem called glaucoma (such as timolol). This may result in loss of the effect of this medicine.
  • medicines that lower the amount of potassium in your blood. These include:
  • steroids (e.g. prednisolone),
  • diuretics (water tablets),
  • medicines for breathing problems such as theophylline. If you take these medicines together with this medicine you may experience symptoms of muscle spasm, muscle weakness or abnormal heart rhythm.
  • medicines called tricyclic antidepressants or MAO inhibitors (like selegiline or moclobemide), that are used to treat neurological or psychiatric disorders like Parkinson's disease or depression; the use of these drugs will increase the likelihood that you get side effects affecting your heart.

Pregnancy, breast-feeding and fertility

Frequently asked questions about Striverdi Respimat 2.5 microgram, solution for inhalation

How do I take Striverdi Respimat 2.5 microgram, solution for inhalation?

Striverdi Respimat 2.5 microgram, solution for inhalation comes as inhaler containing 2.5mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Striverdi Respimat 2.5 microgram, solution for inhalation?

The active substance in Striverdi Respimat 2.5 microgram, solution for inhalation is olodaterol hydrochloride.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Striverdi Respimat 2.5 microgram, solution for inhalation, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Striverdi Respimat 2.5 microgram, solution for inhalation without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Olodaterol hydrochloride (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).

4.2. Posology and method of administration

Posology

The medicinal product is intended for inhalation use only. The cartridge can only be inserted and used in the Respimat inhaler.

Two actuations (puffs) from the Respimat inhaler comprise one medicinal dose.

Adults

The recommended dose is 5 microgram olodaterol given as two actuations (puffs) from the Respimat inhaler once daily, at the same time of the day.

The recommended dose should not be exceeded.

Elderly population

Elderly patients can use Striverdi Respimat at the recommended dose.

Hepatic impairment

Patients with mild and moderate hepatic impairment can use Striverdi Respimat at the recommended dose.

There are no data available for use of Striverdi Respimat in patients with severe hepatic impairment.

Renal impairment

Renally impaired patients can use Striverdi Respimat at the recommended dose. There is limited experience with the use of Striverdi Respimat in patients with severe renal impairment.

Paediatric population

There is no relevant use of Striverdi Respimat in the paediatric population (under 18 years).

Method of administration

This medicinal product is intended for inhalation use only. The cartridge can only be inserted and used in the Respimat re-usable inhaler. Respimat is an inhaler device that generates a spray for inhalation. It is meant for use by a single patient and intended for multiple doses delivered by one cartridge.

The Respimat re-usable inhaler allows for replacement of the cartridge, and can be used with up to 6 cartridges.

Patients should read the instructions on how to use the Respimat re-usable inhaler before they start using Striverdi Respimat.

To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler by a physician or other health care professional.

Instructions for handling and use of the Respimat re-usable inhaler

The patient will need to use this inhaler only ONCE A DAY. Each time used take TWO ACTUATIONS (PUFFS).

• If Striverdi Respimat has not been used for more than 7 days release one actuation (puff) towards the ground.

• If Striverdi Respimat has not been used for more than 21 days repeat steps 4 to 6 under 'Prepare for use' until a cloud is visible. Then repeat steps 4 to 6 three more times.

How to care for the Respimat re-usable inhaler

Clean the mouthpiece including the metal part inside the mouthpiece with a damp cloth or tissue only, at least once a week.

Any minor discoloration in the mouthpiece does not affect the Respimat re-usable inhaler performance.

If necessary, wipe the outside of the Respimat re-usable inhaler with a damp cloth.

When to replace the inhaler

When the patient has used an inhaler with 6 cartridges, get a new Striverdi Respimat pack containing an inhaler. Do not use the Respimat re-usable inhaler for more than one year, after having inserted the first cartridge.

Prepare for use

1. Remove clear base

• Keep the cap closed.

• Press the safety catch while pulling off the clear base with the other hand.

2. Insert cartridge

• Insert the cartridge into the inhaler.

• Place the inhaler on a firm surface and push down firmly until it clicks into place.

3. Track cartridge and put the clear base back

• Mark the check-box on inhaler's label to track the number of cartridges

• Put the clear base back into place until it clicks.

4. Turn

• Keep the cap closed.

• Turn the clear base in the direction of the arrows on the label until it clicks (half a turn).

5. Open

• Open the cap until it snaps fully open.

6. Press

• Point the inhaler toward the ground.

• Press the dose-release button.

• Close the cap.

• Repeat steps 4-6 until a cloud is visible.

• After a cloud is visible, repeat steps 4-6 three more times.

The inhaler is now ready to use and will deliver 60 actuations (puffs) (30 doses).

Daily use

TURN

• Keep the cap closed.

• TURN the clear base in the direction of the arrows on the label until it clicks (half a turn).

OPEN

• OPEN the cap until it snaps fully open.

PRESS

• Breathe out slowly and fully.

• Close the lips around the mouthpiece without covering the air vents. Point the Inhaler to the back of the throat.

• While taking a slow, deep breath through the mouth, PRESS the dose-release button and continue to breathe in slowly for as long as comfortable.

• Hold the breath for 10 seconds or for as long as comfortable.

• Repeat Turn, Open, Press for a total of 2 actuations (puffs).

• Close the cap until the inhaler is used again.

When to replace the Striverdi Respimat cartridge

The dose indicator shows how many actuations (puffs) remain in the cartridge.

60 actuations (puffs) remaining.

Less than 10 actuations (puffs) remaining. Obtain a new cartridge.

The cartridge is used up. Turn the clear base to loosen it. The inhaler is now in a locked position. Pull off the cartridge from the inhaler. Insert a new cartridge until it clicks (refer to step 2). The new cartridge will stick out more than the very first cartridge (continue with step 3). Remember to put the clear base back to unlock the inhaler.

4.3. Contraindications

Striverdi Respimat is contraindicated in patients with hypersensitivity to olodaterol or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Asthma

Striverdi Respimat should not be used in asthma. The long-term efficacy and safety of olodaterol in asthma have not been studied.

Acute bronchospasm

Striverdi Respimat, as a once daily maintenance bronchodilator should not be used for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.

Hypersensitivity

As with all medications, immediate hypersensitivity reactions may occur after administration of Striverdi Respimat.

Paradoxical bronchospasm

As with other inhaled medicines Striverdi Respimat may result in paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs Striverdi Respimat should be discontinued immediately and alternative therapy substituted.

Systemic effects

Long acting beta2-adrenergic agonists should be administered with caution in patients with cardiovascular disorders, especially ischaemic heart disease, severe cardiac decompensation, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, hypertension, and aneurysm, in patients with convulsive disorders or thyrotoxicosis, in patients with known or suspected prolongation of the QT interval (e.g. QT> 0.44 s), and in patients who are unusually responsive to sympathomimetic amines.

Patients with a history of myocardial infarction during the previous year, unstable or life-threatening cardiac arrhythmia, hospitalized for heart failure during the previous year or with a diagnosis of paroxysmal tachycardia (>100 beats per minute) were excluded from the clinical trials. Therefore the experience in these patient groups is limited. Striverdi Respimat should be used with caution in these patient groups.

Cardiovascular effects

Like other beta2-adrenergic agonists, olodaterol may produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms. In case such effects occur, treatment may need to be discontinued. In addition, beta-adrenergic agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave and ST segment depression, although the clinical significance of these observations is unknown.

Hypokalaemia

Beta2-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. In patients with severe COPD, hypokalaemia may be potentiated by hypoxia and concomitant treatment (see section 4.5), which may increase the susceptibility to cardiac arrhythmias.

Hyperglycaemia

Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose.

Anaesthesia

Caution needs to be taken in case of a planned operation with halogenated hydrocarbon anaesthetics due to an increased susceptibility to the adverse cardiac effects of beta agonist bronchodilators.

Excipients

Benzalkonium chloride may cause wheezing and breathing difficulties. Patients with asthma are at an increased risk for these adverse events.

Striverdi Respimat should not be used in conjunction with any other medications containing long-acting beta2-adrenergic agonists.

Patients who have been taking inhaled, short-acting beta2-adrenergic agonists on a regular basis (e.g., four times a day) should be instructed to use them only for symptomatic relief of acute respiratory symptoms.

4.5. Interaction with other medicinal products and other forms of interaction

Adrenergic agents

Concomitant administration of other adrenergic agents (alone or as part of combination therapy) may potentiate the undesirable effects of Striverdi Respimat.

Xanthine derivatives, Steroids or diuretics

Concomitant treatment with xanthine derivatives, steroids, or non-potassium sparing diuretics may potentiate any hypokalemic effect of adrenergic agonists (see section 4.4).

Beta-blockers

Beta-adrenergic blockers may weaken or antagonise the effect of Striverdi Respimat. Therefore Striverdi Respimat should only be given together with beta-adrenergic blockers (including eye-drops) if there are compelling reasons for their use. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

MAO inhibitors and tricyclic antidepressants, QTc Prolonging drugs

Monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval may potentiate the action of Striverdi Respimat on the cardiovascular system.

Pharmacokinetic Drug Drug interactions

No relevant effect on systemic exposure to olodaterol has been observed in drug-drug interaction studies with co-administration of fluconazole, used as model inhibitor of CYP2C9.

Co-administration of ketoconazole as potent P-gp and CYP inhibitor increased systemic exposure to olodaterol by approximately 70%. No dose adjustment is necessary.

Co-administration of olodaterol and tiotropium had no relevant effect on the systemic exposure to either of the two drugs.

In vitro investigations have shown that olodaterol does not inhibit CYP enzymes or drug transporters at the plasma concentrations achieved in clinical practice.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no data from the use of Striverdi Respimat in pregnant women available.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant exposures (see section 5.3).

As a precautionary measure, it is preferable to avoid the use of Striverdi Respimat during pregnancy.

Like other beta2-adrenergic agonists, olodaterol may inhibit labour due to a relaxant effect on uterine smooth muscle.

Breast-feeding

Clinical data from nursing women exposed to olodaterol are not available. It is unknown whether olodaterol/metabolites are excreted in human milk. Available pharmacokinetic/toxicological data in animals have shown excretion of olodaterol and/or its metabolites in milk.

Since the systemic exposure of the breast-feeding woman to olodaterol/metabolites is negligible at the human dose of 5 µg per day, relevant effects on the breastfed newborn/infant are not expected.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Striverdi Respimat therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

Clinical data on fertility are not available for Striverdi Respimat. Preclinical studies performed with olodaterol showed no adverse effect on fertility.

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

However, patients should be advised that dizziness has been reported in clinical trials. Therefore, caution should be recommended when driving a car or operating machinery. If patients experience dizziness, they should avoid potentially hazardous tasks such as driving or operating machinery.

4.8. Undesirable effects

a. Summary of the safety profile

The most common adverse reactions at the recommended dose were nasopharyngitis, dizziness, hypertension, rash and arthralgia. These were usually mild or moderate in intensity.

b. Tabulated summary of adverse reactions

The frequencies assigned to the undesirable effects listed below are based on the crude incidence rates of adverse drug reactions (i.e. events attributed to olodaterol) observed in the olodaterol 5 microgram dose group (1035 patients), pooled from 6 placebo-controlled, parallel group clinical trials in COPD patients with treatment periods ranging between 4 and 48 weeks.

Frequency is defined using the following convention:

Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data)

System Organ Class / MedDRA Preferred Term

Frequency

Infections and infestations

Nasopharyngitis

Uncommon

Nervous system disorders

Dizziness

Uncommon

Vascular disorders

Hypertension

Rare

Skin and subcutaneous tissue disorders

Rash

Uncommon

Musculoskeletal and connective tissue disorders

Arthralgia

Rare

c. Description of selected adverse reactions

Occurrence of rash may be considered a hypersensitivity reaction with Striverdi Respimat; as with all topical absorbed medication, other hypersensitivity reactions may develop.

d. Beta2- agonist adverse reaction profile

Striverdi Respimat is a member of the therapeutic class of long-acting beta2-adrenergic agonists. Therefore, the occurrence of undesirable effects related to the beta-adrenergic agonist class should be taken into consideration, such as tachycardia, arrhythmia, palpitations, myocardial ischaemia, angina pectoris, hypertension or hypotension, tremor, headache, nervousness, insomnia, dizziness, dry mouth, nausea, muscle spasms, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms

An overdose of olodaterol is likely to lead to exaggerated effects typical of beta2-adrenergic agonists, e.g. myocardial ischaemia, hypertension or hypotension, tachycardia, arrhythmias, palpitation, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasms, nausea, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis.

Treatment of overdose

Treatment with Striverdi Respimat should be discontinued. Supportive and symptomatic treatment is indicated. Serious cases should be hospitalised. Use of cardioselective beta-blockers may be considered, but only subject to extreme caution since the use of beta-adrenergic blocker medication may provoke bronchospasm.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • STRIVERDI RESPIMAT 2,5 micrograme prescriptionOLODATEROLUM · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • Striverdi RespimatOlodaterolum · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Striverdi Respimat 2.5 microgram, solution for inhalation. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →